PID1 and cancer: Low levels of ALOXE3, ADRB2, BNC1, BTC, CCNO, ETV4, MCIDAS, PID1, SPRR2D, and ZBTB16 are consistent with the epigenetic repression of pro-differentiation pathways in cancer cells.